Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). (Q38484762)
Jump to navigation
Jump to search
scientific article published on 09 September 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). |
scientific article published on 09 September 2011 |
Statements
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) (English)
Giuseppe Pantaleo
José Luis Jiménez
Mariano Esteban
Beatriz Perdiguero
Carmen E Gómez
Juan Carlos López Bernaldo de Quirós
Judit Pich
Joan Albert Arnaiz
José M Gatell
Jose L Nájera
Victoria Jiménez
Alberto C Guardo
Iñaki Pérez
Matilde Sánchez Conde
Nuria González
Amparo Alvarez
María J Maleno
Jonathan Weber
Montserrat Plana
9 September 2011
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference